Trontinemab

CAS No. 2568868-35-7

Trontinemab( —— )

Catalog No. M37269 CAS No. 2568868-35-7

Trontinemab (RG6102) is a human IgG1-κ antibody selectively targeting Aβ precursor protein (APP) with transferrin receptor p90, CD71 (TFRC), inhibits amyloid production, and can be used to study neurological disorders such as Alzheimer's disease.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
2MG 947 Get Quote
100MG Get Quote Get Quote
200MG Get Quote Get Quote
500MG Get Quote Get Quote
1G Get Quote Get Quote

Biological Information

  • Product Name
    Trontinemab
  • Note
    Research use only, not for human use.
  • Brief Description
    Trontinemab (RG6102) is a human IgG1-κ antibody selectively targeting Aβ precursor protein (APP) with transferrin receptor p90, CD71 (TFRC), inhibits amyloid production, and can be used to study neurological disorders such as Alzheimer's disease.
  • Description
    Trontinemab is a bispecific and humanized IgG1-κ antibody, targeting to amyloid beta A4 precursor protein (APP) and transferrin receptor, p90, CD71 (TFRC). Trontinemab can be used for research on Alzheimer disease (AD).
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    ——
  • Pathway
    Membrane Transporter/Ion Channel
  • Target
    Beta Amyloid
  • Recptor
    Beta Amyloid
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    2568868-35-7
  • Formula Weight
  • Molecular Formula
    ——
  • Purity
    >98% (HPLC)
  • Solubility
    ——
  • SMILES
    ——
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1. Duggan MR, et al. Herpes Viruses in the Baltimore Longitudinal Study of Aging: Associations With Brain Volumes, Cognitive Performance, and Plasma Biomarkers. Neurology. 2022 Aug 19;99(18):e2014–24.?
molnova catalog
related products
  • Hoechst 34580

    Hoechst 34580, a cell-permeable fluorescent dye, is used for staining DNA and nuclei.Hoechst 34580 is a good candidate for treating Alzheimer’s disease by inhibiting Aβ formation. 50 μM Aβ42 solutions co-incubated with 100, 25, 12.5, 3.125, 0.78, and 0.1, 0.01 μM Hoechst 34580 at 37 °C for 70 h. Hoechst 34580 can inhibit the aggregation of Aβ42 in a dose-dependent manner.

  • β-Amyloid 29-40

    β-Amyloid (29-40) is a fragment of Amyloid-β peptide.Alzheimer's beta amyloid peptide (29-40/42) C-terminal fragments have physical and chemical properties related to those of fusion peptides of viral proteins. The fusion of liposomes can be induced by these peptides in vitro.

  • Lecanemab

    Lecanemab (BAN-2401) is an IgG1 monoclonal antibody targeting soluble aggregated β-amyloid (Abeta) with activity against oligomers, protofibrils, and insoluble protofibrils, and may be useful in the study of Alzheimer's disease (AD)-induced mild cognitive impairment and mild AD dementia.